Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis. Review uri icon

Overview

abstract

  • A meta-analysis of randomized controlled trials (RCTs) was performed to examine the risk of everolimus discontinuation due to related and unrelated adverse events (AE) in cancer patients. Fifteen RCTs were analyzed that compared everolimus to placebo and reported discontinuation due to AE with everolimus (related and unrelated to everolimus) and placebo (unrelated to everolimus). Incidence of discontinuation with everolimus due to AE and placebo was 12.3% and 4.7% respectively. Relative risk of everolimus discontinuation due to related AE was 2.60. Risk of discontinuation varied by tumor type, however everolimus dose or concomitant chemotherapy was not significant.

publication date

  • August 11, 2017

Research

keywords

  • Antineoplastic Agents
  • Everolimus
  • Neoplasms

Identity

Scopus Document Identifier

  • 85030466549

Digital Object Identifier (DOI)

  • 10.1080/07357907.2017.1344697

PubMed ID

  • 28799817

Additional Document Info

volume

  • 35

issue

  • 8